TRENDSPOTTER: Don t Let the Market Downturn Derail Your IPO Plans | GenomeWeb

THE HAZY, lazy days of summer are here. But at least in my part of the country, the weather has not heated up and neither have the biotech indices. If anything, they are heading south faster than geese after the first frost. What’s going on? Has biotech gone out of favor once again? No, I think what we are seeing is investor reaction to the FDA. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.